SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: DRS/A
Document Type: DRS/A
Date Filed: 2025-10-06
Accession Number: 0001493152-25-016953
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315225016953/filename1.htm

Chunk 0 of 87
Word Count: 1357
Character Count: 8880

Document Content:

Confidentially
submitted to the Securities and Exchange Commission on October 3, 2025 as Amendment No. 1 to the draft registration statement.

This Amendment No. 1 to the draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission
and all information herein remains strictly confidential.

Registration

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,

FORM

REGISTRATION
STATEMENT

UNDER

THE
SECURITIES ACT OF 1933

BIOVENTRIX,
INC.

(Exact
Name of Registrant as Specified in its Charter)

Delaware 3841 20-0372415

(State
or other jurisdiction of
incorporation
or organization) (Primary
Standard Industrial
Classification
Code Number) (I.R.S.
Employer
Identification No.)

Forbes Blvd., Suite 125

Mansfield, MA 02048 USA

(Address,
Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

David
Richmond

Chairman
and Chief Executive Officer

Forbes Blvd., Suite 125

Mansfield, MA 02048 USA

(Name,
Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

with
copies to:

Richard
I. Anslow, Esq.
Lawrence
A. Rosenbloom, Esq.
Ellenoff
Grossman & Schole LLP
Avenue of the Americas
New
York, NY 10105
Phone:
Fax:
(212) 370-7889 Stephen
E. Older, Esq.
Carly
E. Ginley, Esq.
McGuireWoods
LLP
Avenue of the Americas, 20 th Floor
New
York, NY 10020
Phone:
Fax:

Approximate
date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act, check the following box. ☒

this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration number of the earlier effective registration statement for the same offering. ☐

this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration number of the earlier effective registration statement for the same offering. ☐

Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large
accelerated filer ☐ Accelerated
filer ☐ Non-accelerated
filer ☒ Smaller
reporting company ☒

Emerging
growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective
on such date as the U.S. Securities and Exchange Commission, acting pursuant to Section 8(a), may determine.

The
information contained in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration
statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these
securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

PRELIMINARY
PROSPECTUS	SUBJECT
TO COMPLETION, DATED [●], 2025

Shares

Common
Stock

This
is the initial public offering of        shares of common stock, par value $0.0001 per share, of
BioVentrix, Inc., a Delaware corporation, on a firm commitment basis.

Prior
to this offering, there has been no public market for our common stock. We anticipate that the initial public offering price of our common
stock will be between $      and $         per share with a $
assumed initial public offering price (which is the midpoint of the $       and $
per share range; this assumption is used throughout this prospectus). We intend to apply to have our common stock listed on the Nasdaq
Capital Market (“Nasdaq”) under the symbol “BVXX.” No assurance can be given that our application will be approved
by Nasdaq. If our common stock is not approved for listing on Nasdaq, we will not consummate this offering.

The
initial public offering price of our shares of common stock in this offering will be determined between the underwriters and us at the
time of pricing, considering our historical performance and capital structure, prevailing market conditions, and overall assessment of
our business. Therefore, the assumed initial public offering price used throughout this prospectus may not be indicative of the final
offering price.

are an emerging growth company under the Jumpstart Our Business Startups Act of 2012 and a “smaller reporting company” as
defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and, as such, may elect to
comply with certain reduced public company reporting requirements for this prospectus and future filings. See “Summary —
Implications of Being an Emerging Growth Company” and “Summary — Implications of Being a Smaller Reporting Company.”

Investing
in our common stock is speculative and involves a high degree of risk. Before making any investment decision, you should carefully
review and consider all the information in this prospectus, including the risks and uncertainties described under “Risk
Factors” beginning on page 10.

Neither
the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

Per
Share Total

Initial public offering price $ $

Underwriting discounts and
commissions (1) $ $

Proceeds to us, before expenses $ $

(1)	Represents
underwriting discounts equal to seven percent (7%) of the gross proceeds from sales of shares of common stock in this offering. For
a description of the other terms of compensation to be received by the underwriters, see “ Underwriting .”

have agreed to issue a warrant to the representative of the underwriters to purchase a number of shares of common stock equal to five
percent (5%) of the total number of shares of common stock sold in this offering (including any shares of common stock sold pursuant
to the exercise of the underwriters’ over-allotment option), at an exercise price equal to the initial public offering price of
the shares of common stock sold in this offering. The registration statement of which this prospectus is a part also registers the offer
and sale of the representative’s warrant and the shares of our common stock issuable upon exercise thereof.

have granted a 30-day option to the underwriters to purchase up to        additional shares of common
stock at the initial public offering price, less underwriting discounts and commissions, solely to cover over-allotments, if any.
If the underwriters exercise the option in full, the total underwriting discounts and commissions will be $         and
the additional proceeds to us, before expenses, from the over-allotment option exercise will be $

The
underwriters expect to deliver the shares of common stock to purchasers on or about

Benchmark,
a StoneX Company

The
date of this prospectus is               , 2025

TABLE
OF CONTENTS

Page

Prospectus
Summary 1

Risk
Factors 10

Cautionary Note Regarding Forward-Looking Statements 57

Use of Proceeds 58

Dividend Policy 59

Capitalization 60

Dilution 61

Management’s Discussion and Analysis of Financial Condition and Results of Operations 63

Business 70

Management 86

Executive and Director Compensation 91

Principal Stockholders 100

Certain Relationships and Related Party Transactions 102

Description of Capital Stock 103

Shares Eligible for Future Sale 109

Material U.S. Federal Income Tax Consequences to Non-U.S. Holders 111

Underwriting 115

Legal Matters 124

Experts 124

Where You Can Find More Information 124

Index to Consolidated Financial Statements F-1